ASX:AC8

AusCann Group (AC8) Stock Price, News & Analysis

Today's Range
N/A
50-Day Range
N/A
52-Week Range
N/A
Volume
537,446 shs
Average Volume
N/A
Market Capitalization
N/A
P/E Ratio
N/A
Dividend Yield
6.79%
Price Target
N/A

About AusCann Group

AusCann Group Holdings Ltd engages in the development and commercialization of cannabinoid-derived therapeutic products for humans and animals in Australia and internationally. Its principal product includes the novel tetrahydrocannabinol and cannabidiol (THC/CBD), a powder-based hard-shell capsules based on AusCann's Neuvis platform for the treatment of pain and related indications. The company is also involved in the research and development of medicinal cannabis. It offers its products to healthcare professionals and veterinarians. AusCann Group Holdings Ltd is based in West Perth, Australia.

AC8 Stock News Headlines

Automatic Income (from home)
For over 22 years, Wall Street elites have kept this little-known "income hack" from everyday investors… 6 simple clicks have set up HUGE payouts for "in-the-know" investors… Delivering them passive income 365 days a year.
AC8.AX - AusCann Group Holdings Ltd
ACNNF AusCann Group Holdings Ltd
Automatic Income (from home)
For over 22 years, Wall Street elites have kept this little-known "income hack" from everyday investors… 6 simple clicks have set up HUGE payouts for "in-the-know" investors… Delivering them passive income 365 days a year.
ASX pot stock update: What you need to know
AusCann Group Holdings Ltd.
See More Headlines
Receive AC8 Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for AusCann Group and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Sector
Medical
Industry
Drug Manufacturers - Specialty & Generic
Sub-Industry
N/A
CIK
N/A
Fax
N/A
Employees
N/A
Year Founded
N/A

Profitability

Net Income
$-10,700,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$1.55 million
Book Value
A$0.02 per share

Miscellaneous

Free Float
N/A
Optionable
Not Optionable
Beta
0.73
20 Stocks to Sell Now Cover

MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.

Get This Free Report

Key Executives

  • Mr. Christopher Mews A.C.I.S.
    B. Bus, C.P.A., Chief Financial Officer
  • Ms. Rachel Jelleff Kerr
    Company Secretary

AC8 Stock Analysis - Frequently Asked Questions

What other stocks do shareholders of AusCann Group own?
This page (ASX:AC8) was last updated on 5/5/2024 by MarketBeat.com Staff

From Our Partners